News Sentiment

TRVI sentiment intelligence

Trevi Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 19.07 Week of 17 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

75/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+6.9% over one week, +10.8% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

BMO Capital Initiates Trevi Therapeutics at Outperform With $36 Price Target

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 75/100 classification
One-week reaction 6.9% Price confirming higher
Trend fit Trend active 10.8% over four weeks
Fair value 207.4% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 34
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
MarketBeat 9
Market source 9
TradingView 7
simplywall.st 5
Investing.com 4
MT Newswires 3
timothysykes.com 3
www.marketscreener.com 3

Event Lens

What the news is about

Classified themes
Market update 24
Earnings 21
Analyst action 6
Balance sheet 6
Guidance 4

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 61
TradingView Direct company coverage

Price to book forward of Trevi Therapeutics, Inc. – NASDAQ:TRVI

This page provides access to the "Price to book forward" financial metric for Trevi Therapeutics, Inc. (NASDAQ: TRVI). It serves as a financial data portal within a larger trading platform, allowing users to view specific financial indicators for the biotechnology company.

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 04:44
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Trevi Therapeutics, Inc. – BOATS:TRVI

This article provides a financial snapshot for Trevi Therapeutics, Inc. (TRVI) on the Blue Ocean Alternative Trade System (BOATS). It specifically mentions the "Price to earnings forward" metric, along with general financial and market data availability. The content primarily foc

Tone
Neutral 50/100
Event
Earnings
Published
08 Jul 2026 03:44
Source
TradingView
Investing.com Nigeria Direct company coverage

Trevi Therapeutics stock hits all-time high at 19.33 USD By Investing.com

Trevi Therapeutics (TRVI) stock reached an all-time high of $19.33, reflecting a 226.05% increase over the past year. The company reported strong Q1 2026 earnings with a pro forma cash balance of $334 million and plans to initiate a pivotal program for Haduvio in IPF-CC, with dat

Tone
Positive 72/100
Event
Earnings
Published
07 Jul 2026 22:10
Source
Investing.com Nigeria
Simply Wall Street Direct company coverage

Should Trevi’s Multi‑Index Russell Exit Reshape How Haduvio Drives the Trevi Therapeutics (TRVI) Story?

Trevi Therapeutics (TRVI) was delisted from several Russell indices in late June 2026, which could impact its institutional ownership and trading volume. This event, however, does not fundamentally change the Haduvio development narrative, though it highlights the company's relia

Tone
Negative 38/100
Event
Market update
Published
06 Jul 2026 01:11
Source
Simply Wall Street
www.marketscreener.com Direct company coverage

Trevi Therapeutics, Inc.(NasdaqGM: TRVI) dropped from Russell 3000E Growth Benchmark

Trevi Therapeutics, Inc. (NasdaqGM: TRVI) has been removed from the Russell 3000E Growth Benchmark. The company, a clinical-stage biopharmaceutical firm, is focused on developing Haduvio (oral nalbuphine ER) for conditions like chronic cough in IPF patients and refractory chronic

Tone
Negative 37/100
Event
Market update
Published
30 Jun 2026 07:09
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Trevi Therapeutics, Inc.(NasdaqGM: TRVI) dropped from Russell 3000E Index

Trevi Therapeutics, Inc. (NasdaqGM: TRVI) has been removed from the Russell 3000E Index as of June 29, 2026. This publicly traded biopharmaceutical company focuses on developing Haduvio (oral nalbuphine ER) for chronic cough and pruritus treatments. The article also provides rece

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 12:50
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Trevi Therapeutics, Inc.(NasdaqGM:TRVI) dropped from Russell Microcap Index

Trevi Therapeutics, Inc. (TRVI) has been removed from the Russell Microcap Index, following an earlier removal from the Russell 3000E Index. The clinical-stage biopharmaceutical company, which is developing Haduvio for chronic cough and pruritus, has also recently seen lock-up ag

Tone
Negative 30/100
Event
Market update
Published
29 Jun 2026 05:33
Source
www.marketscreener.com
TradingView Direct company coverage

Trevi Therapeutics, Inc. Actuals & Estimates (NASDAQ:TRVI)

This article provides an overview of Trevi Therapeutics, Inc. (NASDAQ:TRVI) stock, including its current price, historical performance, and analyst forecasts. It details financial metrics, earnings estimates, market capitalization, and volatility, along with information on future

Tone
Positive 70/100
Event
Earnings
Published
26 Jun 2026 06:41
Source
TradingView
TradingView Direct company coverage

TRVI Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Trevi Therapeutics, Inc. (TRVI) stock, based on analyst opinions. It details the current stock performance, historical highs and lows, market capitalization, and financial information such as earnings and revenue, along with a

Tone
Positive 67/100
Event
Earnings
Published
25 Jun 2026 17:39
Source
TradingView